Raritan, NJ, United States of America

Vernon Alford


Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2004-2005

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Vernon Alford

Introduction

Vernon Alford is a notable inventor based in Raritan, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for pain treatment. With a total of 2 patents, Alford's work has the potential to impact many lives.

Latest Patents

Alford's latest patents include a compound known as 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione. This compound is designed for the treatment of pain and includes both its (−) enantiomer and its (+) enantiomer, along with pharmaceutically-acceptable salts. The patent outlines a method for treating pain by administering a pain-ameliorating effective amount of the (−) enantiomer to individuals suffering from pain. Additionally, Alford has developed compounds useful for pain treatment, as described in structural diagram (I), which includes tautomers and pharmaceutically-acceptable salts.

Career Highlights

Vernon Alford is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on innovative solutions for pain management, contributing to the advancement of medical science.

Collaborations

Alford has collaborated with notable colleagues such as Dean Brown and Rebecca Urbanek. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.

Conclusion

Vernon Alford's contributions to the field of pharmaceuticals, particularly in pain treatment, highlight his innovative spirit and dedication to improving healthcare. His patents and collaborations reflect a commitment to advancing medical science for the benefit of patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…